Across TCGA pan-cancer cohorts, ZNRF1 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ZNRF1 data layer compared with 20 for mass-spec protein and 5 for mutation status.
The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ZNRF1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ZNRF1 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.
PDAC, HNSC, and LUAD are the cancer types where ZNRF1 mass-spec protein most reproducibly stratifies survival.